9,419 results match your criteria Breast cancer research and treatment[Journal]


Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.

Breast Cancer Res Treat 2020 Jul 10. Epub 2020 Jul 10.

Department of Surgery, Section of Endocrine and Oncologic Surgery, Washington University St. Louis, St. Louis, MO, USA.

Purpose: To evaluate the cost-effectiveness of axillary observation versus sentinel lymph node biopsy (SLNB) after negative axillary ultrasound (AUS). In patients with clinical T1-T2 N0 breast cancer and negative AUS, SLNB is the current standard of care for axillary staging. However, SLNB is costly, invasive, decreasing in importance for medical decision-making, and is not considered therapeutic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05768-2DOI Listing

Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation.

Breast Cancer Res Treat 2020 Jul 10. Epub 2020 Jul 10.

Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.

Purpose: Although regional nodal irradiation (RNI) improves outcomes in breast cancer (BC) patients, it is associated with increased toxicity. Therefore, controversy still exists surrounding its indications. The purpose of this study was to evaluate and compare patient-reported acute fatigue in elderly BC patients with and without regional nodal radiation (RNI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05781-5DOI Listing

Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study.

Breast Cancer Res Treat 2020 Jul 10. Epub 2020 Jul 10.

Analytical Epidemiology and Health Impact Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy.

Purpose: Endocrine therapy (ET) is the mainstream adjuvant treatment for ER-positive breast cancer (BC). We analysed 9293 ER-positive BC patients diagnosed in nine European countries in 2009-2013 to investigate how comorbidities at diagnosis, age, stage and subtype affected ET use over time, and relapse.

Methods: Adjusted odds ratios (ORs) and 95% confidence intervals (95%CIs) of receiving ET were estimated according to Charlson comorbidity, age, stage and subtype using logistic regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05761-9DOI Listing

Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial.

Breast Cancer Res Treat 2020 Jul 9. Epub 2020 Jul 9.

Department of Radiation Oncology, Max Superspecialty Hospital, Vaishali, Ghaziabad, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05790-4DOI Listing

Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.

Breast Cancer Res Treat 2020 Jul 9. Epub 2020 Jul 9.

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Purpose: To evaluate the effect of adjuvant chemotherapy on improving the prognosis of patients with stage I triple-negative breast cancer (TNBC).

Methods: TNBC patients diagnosed in the SEER 18 database from 2010 to 2015 were included. Kaplan-Meier plots and log-rank tests were used to compare the differences in breast cancer-specific survival (BCSS) and overall survival (OS) between subgroups of variables. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05776-2DOI Listing

Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.

Breast Cancer Res Treat 2020 Jul 9. Epub 2020 Jul 9.

Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (Unit 1464), Houston, TX, 77030, USA.

Purpose: Approximately 70% of patients with metastatic breast cancer (MBC) are hormone receptor (HR)-positive. Recent studies have shown that CDK4/6 inhibitors (CDKI) improve survival in combination with ET in HR-positive, HER2-negative MBC. The risk of venous thromboembolism (VTE) is 3-4 times higher in patients with breast cancer (BC) than in patients without cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05783-3DOI Listing

Assessing preferences for receiving supportive care resources among patients seen at a Breast Care Center.

Breast Cancer Res Treat 2020 Jul 9. Epub 2020 Jul 9.

University of California San Francisco, San Francisco, California, USA.

Background: Patients with breast cancer or at high risk for breast cancer have supportive care needs. Although cancer centers offer social, psychological, and other support to these patients, these services are not always utilized, and patients continue to report unmet supportive care needs. Reasons for non-utilization of these services have not been well documented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05786-0DOI Listing

External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery.

Breast Cancer Res Treat 2020 Jul 9. Epub 2020 Jul 9.

Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.

Purpose: A positive resection margin after breast conserving surgery (BCS) is the most important risk factor for tumor recurrence. In 2012, Seoul National University Hospital (SNUH) breast surgery team developed a nomogram for predicting positive resection margins before BCS to provide individual surgical plans that could reduce local recurrence without increasing re-excision rates. The purpose of this study was to validate this nomogram using an external cohort and to test if addition of surgeon-related factor could improve its use as a predictive model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05779-zDOI Listing

Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.

Breast Cancer Res Treat 2020 Jul 8. Epub 2020 Jul 8.

Biostatistics Branch, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.

In the original publication of the article, the first sentence in the abstract was published incorrectly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05775-3DOI Listing

Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.

Breast Cancer Res Treat 2020 Jul 7. Epub 2020 Jul 7.

Institute of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12., CH-8091, Zurich, Switzerland.

Purpose: Human epidermal growth factor-receptor-2 (HER2) is a membrane-tyrosine-kinase that is amplified/overexpressed up to 20% in breast cancer. HER2 positive status is associated with faster disease progression, higher metastatic potential, and shorter disease-free/overall survival and also has emerged as an important therapeutic target in breast cancer. HER2 status can be determined by in-situ-hybridization (ISH) or immunohistochemistry (IHC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05772-6DOI Listing

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.

Breast Cancer Res Treat 2020 Jul 7. Epub 2020 Jul 7.

Department of Breast Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China.

Purpose: Despite the therapeutic success of existing HER2-targeted therapies, tumors respond quite differently to them. This study aimed at figuring out genetic mutation profile of Chinese HER2-positive patients and investigating predictive factors of neoadjuvant anti-HER2 responses.

Methods: We employed two cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05778-0DOI Listing

Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.

Breast Cancer Res Treat 2020 Jul 6. Epub 2020 Jul 6.

Department of Medicine, Division of Clinical Pharmacology, Western University, London, ON, Canada.

Purpose: Female patients with breast cancer frequently develop arthralgia when treated with aromatase inhibitors (AI). Although the mechanism of AI-induced arthralgia is unknown, potential biomarkers have been identified. The purpose of this study was to investigate the clinical and genetic predictors of AI-induced arthralgia in a prospective cohort of patients with estrogen receptor-positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05777-1DOI Listing

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations.

Breast Cancer Res Treat 2020 Jul 6. Epub 2020 Jul 6.

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Purpose: EUSOMA's recommendation that "each patient has to be fully informed about each step in the diagnostic and therapeutic pathway" could be supported by guideline-based clinical decision trees (CDTs). The Dutch breast cancer guideline has been modeled into CDTs ( www.oncoguide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05769-1DOI Listing

Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?

Breast Cancer Res Treat 2020 Jul 3. Epub 2020 Jul 3.

Center for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.

Purpose: Women at an elevated lifetime risk for breast cancer (BC), including carriers of pathogenic mutations in BC predisposition genes, are recommended intensified BC screening that includes annual mammography (MG) and annual breast MRI. Controversy exists regarding the clinical utility of MRI as a screening tool in high-risk women. This paper is intended to review recent advances and remaining areas of uncertainty in order to further facilitate the incorporation of breast MRI into an intensified BC screening protocol for women at high familial risk and BRCA carriers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05759-3DOI Listing

Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.

Breast Cancer Res Treat 2020 Jul 3. Epub 2020 Jul 3.

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Purpose: The prognostic role of tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer (BC) is debated. We evaluated the association of TILs and clinico-pathological features with distant disease-free survival (DDFS) in patients with ER+/HER2- BC treated at a single institution.

Patients And Methods: A mono-institutional case-cohort series of 987 patients with early ER+/HER2- BC was retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05771-7DOI Listing

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.

Breast Cancer Res Treat 2020 Jul 1. Epub 2020 Jul 1.

Department of Obstetrics and Gynecology, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.

Background: The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications.

Patients And Methods: In all, 541 patients with available receptor statuses from both primary tumor and metastatic lesion treated at Heidelberg and Tuebingen University Hospitals between 1982 and 2018 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05746-8DOI Listing

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.

Breast Cancer Res Treat 2020 Jun 29. Epub 2020 Jun 29.

Memorial Sloan-Kettering Cancer Center, 60th St Outpatient Center; 16 East 60th St, New York, NY, 10022, USA.

Purpose: Rash develops in approximately 50% of patients receiving alpelisib for breast cancer, often requiring dose modifications. Here, we describe the clinicopathologic, laboratory, and management characteristics of alpelisib-related dermatologic adverse events (dAEs).

Methods: A single center-retrospective analysis was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05726-yDOI Listing

Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery.

Breast Cancer Res Treat 2020 Jul 1. Epub 2020 Jul 1.

Department of Surgery, Huntington Hospital, 100 W California Blvd, Pasadena, CA, 91105, USA.

Purpose: A positive margin after breast conserving surgery has consistently been shown to be a significant predictor for ipsilateral breast tumor recurrence. Currently, there is no standard for intraoperative margin assessment during lumpectomy, and up to 20% of cases result in positive margins. MarginProbe is a device that provides real-time evaluation of lumpectomy margins during surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05773-5DOI Listing

Association between selenium intake and breast cancer risk: results from the Women's Health Initiative.

Breast Cancer Res Treat 2020 Jun 30. Epub 2020 Jun 30.

Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, 1025 E 7th street, Bloomington, IN, 47405, USA.

Purpose: It has been hypothesized that selenium (Se) can prevent cancer, and that Se deficiency may be associated with an increased risk of breast cancer. However, findings from epidemiological studies have been inconsistent. The objective of this study was to assess the association between Se intake and risk of breast cancer in the Women's Health Initiative (WHI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05764-6DOI Listing

Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy.

Breast Cancer Res Treat 2020 Jun 30. Epub 2020 Jun 30.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

Purpose: To explore the optimal type of breast reconstruction and the time interval to postmastectomy radiotherapy (PMRT) associated with lower complications in breast cancer patients receiving neoadjuvant chemotherapy.

Methods: We reviewed the medical records of 300 patients who received neoadjuvant chemotherapy, mastectomy with breast reconstruction and PMRT at our institution from 2000 to 2017. Reconstruction types included autologous flaps (AR), single-stage-direct-to-implant and two-stages expander/implant (TE/I). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05747-7DOI Listing

Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.

Breast Cancer Res Treat 2020 Jun 29. Epub 2020 Jun 29.

Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

Purpose: The aim of the current study was to evaluate the effect of N-acetylcysteine (NAC) on the incidence and severity of paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients.

Method: A prospective randomized controlled open label study was conducted on 75 breast cancer patients receiving adjuvant paclitaxel 80 mg/m weekly for 12 weeks. Eligible patients were randomized to either the low dose group; 1200 mg daily NAC, the high dose group; 1200 mg NAC twice daily or the control group; received paclitaxel only. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05762-8DOI Listing

A case for Tamoxifen with ovarian function suppression.

Breast Cancer Res Treat 2020 Jun 29. Epub 2020 Jun 29.

University of Florida, 1600 SW Archer Road, PO Box 100278, Gainesville, FL, 32610, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05766-4DOI Listing

CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.

Breast Cancer Res Treat 2020 Jun 29. Epub 2020 Jun 29.

Department of Breast Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Hefei, 230022, Anhui, China.

Background: Triple-negative breast cancer (TNBC) remains a great challenge in clinical treatment due to a shortage of effective therapeutic targets and acquired chemoresistance. Here, we identified the role of an RNA-binding protein, CUG-BP Elav-like family member 6 (CELF6), in the TNBC development and paclitaxel (PTX) chemoresistance.

Methods: Stable CELF6-overexpressing cell lines were established in BT549 and MDA-MB-231 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05753-9DOI Listing

Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer.

Breast Cancer Res Treat 2020 Jun 29. Epub 2020 Jun 29.

Division of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan, ROC.

Purpose: Mitochondrial unfolding protein are abundant in breast cancer cells, but the mechanism by which breast cancer cells resist apoptosis is still not fully elucidated. In this study, we explored the role of mitochondrial unfolded protein response (mtUPR)-related proteins in four types of breast cancer tissues.

Methods: Mitochondrial fractions were taken from four breast cancer tissues (luminal A, luminal B, Her2 -overexpression, and TNBC) and the expression of mitochondrial polyubiquitinated proteins was observed by western blot and ELISA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05729-9DOI Listing

Magnetic resonance imaging and bioimpedance evaluation of lymphatic abnormalities in patients with breast cancer treatment-related lymphedema.

Breast Cancer Res Treat 2020 Jun 29. Epub 2020 Jun 29.

Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.

Purpose: Breast cancer treatment-related lymphedema (BCRL) evaluation is frequently performed using portable measures of limb volume and bioimpedance asymmetry. Here quantitative magnetic resonance imaging (MRI) is applied to evaluate deep and superficial tissue impairment, in both surgical and contralateral quadrants, to test the hypothesis that BCRL impairment is frequently bilateral and extends beyond regions commonly evaluated with portable external devices.

Methods: 3-T MRI was applied to investigate BCRL topographical impairment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05765-5DOI Listing

Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.

Authors:
Dingxie Liu

Breast Cancer Res Treat 2020 Jun 29. Epub 2020 Jun 29.

Bluewater Biotech LLC, PO Box 1010, New Providence, NJ, 07974, USA.

Purpose: The development of multi-gene signatures has led to improvements in identification of breast cancer patients at high risk of recurrence. The prognostic power of commercially available gene signatures is mostly restricted to estrogen receptor (ER)-positive breast cancer. On the contrary, immune-related gene signatures predict prognosis only in ER-negative breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05770-8DOI Listing

Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.

Breast Cancer Res Treat 2020 Jun 28. Epub 2020 Jun 28.

Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05767-3DOI Listing

Standardize the management procedures for breast cancer patients during the outbreak of COVID-19 in Wuhan, China.

Breast Cancer Res Treat 2020 Jun 27. Epub 2020 Jun 27.

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Road 1277, Wuhan, 430022, China.

Purpose: The outbreak of the coronavirus disease 2019 (COVID-19) has led to interruption or delay in treatment of breast cancer patient. This commentary aims to standardize the management procedures and ensure complete or relatively complete treatment for breast cancer patients during the outbreak of COVID-19.

Methods: Provide detailed online diagnosis, online treatment recommendations, and face-to-face consultation suggestions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05743-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320838PMC

Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data.

Breast Cancer Res Treat 2020 Jun 26. Epub 2020 Jun 26.

Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.

Purpose: The incidence and predictors of diabetes (DM) in patients with breast cancer (BC) were evaluated. We compared DM incidence and physician access in BC patients to matched controls.

Methods: We identified women with stage I-III BC diagnosed from 2005 to 2013 in the SEER-Medicare database, with ≥ 2 years of follow-up after diagnosis, without previous DM claims. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05756-6DOI Listing

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.

Breast Cancer Res Treat 2020 Jun 26. Epub 2020 Jun 26.

Mount Sinai Hospital, New York, NY, USA.

Purpose: Anti-human epidermal growth factor receptor 2 (HER2) therapies are associated with interstitial lung disease (ILD), also referred to as pneumonitis. In this literature review, we describe the incidence of ILD among patients with HER2-positive metastatic breast cancer (MBC) receiving anti-HER2 therapies, and we describe existing recommendations for monitoring and managing drug-induced ILD among these patients.

Methods: We searched PubMed and Embase to identify clinical trials and postmarket observational studies that investigated anti-HER2 therapies for HER2-positive MBC, reported on ILD, and were published during January 1, 2009 to July 15, 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05754-8DOI Listing

Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.

Breast Cancer Res Treat 2020 Jun 26. Epub 2020 Jun 26.

Centre for Research on Health and Social Care Management (Cergas), SDA Bocconi School of Management, Milan, Italy.

Purpose: Adjuvant endocrine therapy (AET) for ≥ 5 years is generally recommended for women with hormone receptor-positive breast cancer to reduce cancer recurrence/mortality; however, adherence can be suboptimal. We tested determinants of AET adherence using patient characteristics, treatment pathways, AET initiation timing, and multiple healthcare facility use. An underlying objective was to explore how oncological pathways mirror chronic disease management to monitor adherence and target improvement interventions using administrative datasets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05748-6DOI Listing

Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study.

Breast Cancer Res Treat 2020 Jun 25. Epub 2020 Jun 25.

Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.

Aims: To assess the existence, components and clinical relevance of cardiac causes of death and cardiovascular (CV) hospitalizations in a population-wide database of patients with breast cancer (BC).

Methods And Results: A population-wide database of the Puglia Region, Italy was analyzed, with a prospective comparative design. Three successive closely matched case/control cohorts representing current care in the period 2007-2014 were also stratified according to age to focus specifically on the potential interaction of treatment-related cardiac toxicity and the expected different baseline CV risk profiles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05758-4DOI Listing

Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.

Breast Cancer Res Treat 2020 Jun 23. Epub 2020 Jun 23.

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Purpose: Neutropenia is the most common toxicity of CDK4/6 inhibitors, causing frequent dose interruptions. However, CDK4/6 inhibitor-induced neutropenia shows a benign clinical course in contrast to that caused by chemotherapy. Here, we investigated the safety of a new dose scheme for palbociclib, which avoids dose delays or reductions due to afebrile grade 3 neutropenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05750-yDOI Listing

A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer.

Breast Cancer Res Treat 2020 Jun 23. Epub 2020 Jun 23.

SHORE-C, Brighton and Sussex Medical School, Brighton, BN1 9RX, England.

Purpose: This systematic review examined educational training interventions for healthcare professionals (HCPs) discussing genetic testing and risk for hereditary breast cancer. There was a particular focus on the presence, and content, of communication elements within these packages.

Methods: Searches were run via CINAHL, EMBASE, PUBMED, and PsychInfo in February 2019 to identify training interventions available to HCPs with reference to communication skills. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05741-zDOI Listing

Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.

Breast Cancer Res Treat 2020 Jun 23. Epub 2020 Jun 23.

School of Medicine, University of Leeds, Leeds, UK.

Purpose: Breast cancer tumour-infiltrating lymphocytes associate with clinico-pathological factors, including survival, although the literature includes many conflicting findings. Our aim was to assess these associations for key lymphocyte subtypes and in different tumour compartments, to determine whether these provide differential correlations and could, therefore, explain published inconsistencies. Uniquely, we also examine whether infiltrating levels merely reflect systemic lymphocyte levels or whether local factors are predominant in recruitment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05757-5DOI Listing

Impact of NR5A2 and RYR2 3'UTR polymorphisms on the risk of breast cancer in a Chinese Han population.

Breast Cancer Res Treat 2020 Jun 23. Epub 2020 Jun 23.

Department of Internal Medicine Oncology, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine, Xi'an, 710061, Shaanxi, China.

Objectives: The NR5A2 and RYR2 genes are important players in steroid metabolism and play an important role in cancer research. In this research, we want to evaluate the effect of NR5A2 and RYR2 polymorphisms on breast cancer (BC).

Methods: Four single nucleotide polymorphisms on NR5A2 and RYR2 were selected to genotype by Agena MassARRAY in 379 BC patients and 407 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05736-wDOI Listing

Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.

Breast Cancer Res Treat 2020 Jun 22. Epub 2020 Jun 22.

Department of Oncology and Pathology, CCK, Karolinska Institutet, R8:04, 17176, Stockholm, Sweden.

Purpose: The proliferation-associated biomarker Ki67 has potential utility in breast cancer, including aiding decisions based on prognosis, but has unacceptable inter- and intralaboratory variability. The aim of this study was to compare the prognostic potential for Ki67 hot spot scoring and global scoring using different digital image analysis (DIA) platforms.

Methods: An ER+/HER2- breast cancer cohort (n = 139) with whole slide images of sequential sections stained for hematoxylin-eosin, pancytokeratin and Ki67, was analyzed using two DIA platforms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05752-wDOI Listing

Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.

Breast Cancer Res Treat 2020 Jun 22. Epub 2020 Jun 22.

Department of Oncology, Aarhus University Hospital/Aarhus University, Entrance C, Level 1, C118, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.

Purpose: To examine the association between statin use and risk of breast cancer recurrence in a national Danish cohort of postmenopausal breast cancer patients receiving aromatase inhibitors (AI) in the adjuvant setting.

Patients And Methods: We enrolled all postmenopausal patients diagnosed with stage I-III estrogen receptor positive breast cancer during the years 2007-2017, assigned adjuvant AI treatment, and registered in both the Danish Breast Cancer Group database and the Danish Cancer Registry. We ascertained incident statin exposure (≥ 1 prescription post-diagnosis) from the Danish National Prescription Registry and modeled statins as a time-varying exposure lagged by 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05749-5DOI Listing

High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.

Breast Cancer Res Treat 2020 Jun 22. Epub 2020 Jun 22.

Department of Breast Oncology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.

Background: Multi-gene expression assays have been developed with the aim of predicting late recurrence in patients with estrogen receptor (ER)-positive breast cancer. However, establishment of alternative markers based on immunohistochemistry is also important for achieving practical use. Based on our previous study, forkhead box A1 (FOXA1) protein was tested as a potentially useful predictive marker for late recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05751-xDOI Listing

Hormone replacement therapy and mammographic density: a systematic literature review.

Breast Cancer Res Treat 2020 Aug 22;182(3):555-579. Epub 2020 Jun 22.

Section of Environmental Health, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Purpose: Hormone replacement therapy (HRT) is used to reduce climacteric symptoms of menopause and prevent osteoporosis; however, it increases risk of breast cancer. Mammographic density (MD) is also a strong risk factor for breast cancer. We conducted this review to investigate the association between HRT use and MD and to assess the effect of different HRT regimens on MD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05744-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320951PMC

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.

Breast Cancer Res Treat 2020 Aug 20;182(3):689-697. Epub 2020 Jun 20.

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Purpose: The Chinese bridging study PUFFIN (NCT02896855) aimed to assess consistency of efficacy with CLEOPATRA (NCT00567190), investigating pertuzumab with trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer.

Methods: Patients were randomized 1:1, stratified by visceral/non-visceral disease and hormone receptor status. The primary endpoint was investigator-assessed progression-free survival (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05728-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320929PMC

Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.

Breast Cancer Res Treat 2020 08;182(3):765

Genetic Pathology Evaluation Centre and University of British Columbia, Vancouver, BC, Canada.

In the original publication of the article, the funding statement was published incompletely. The corrected funding statement should read as below. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05745-9DOI Listing

High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis.

Breast Cancer Res Treat 2020 Aug 19;182(3):679-688. Epub 2020 Jun 19.

Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, USA.

Purpose: As our hospitals conserve and re-allocate resources during the COVID-19 crisis, there is urgent need to determine how best to continue caring for breast cancer patients. During the time window before the COVID-19 critical peak and particularly thereafter, as hospitals are able to resume cancer operations, we anticipate that there will be great need to maximize efficiency to treat breast cancer. The goal of this study is to present a same-day protocol that minimizes resource utilization to enable hospitals to increase inpatient capacity, while providing care for breast cancer patients undergoing mastectomy and immediate breast reconstruction during the COVID-19 crisis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05739-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304917PMC

Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.

Breast Cancer Res Treat 2020 Aug 19;182(3):665-677. Epub 2020 Jun 19.

Comprehensive Breast Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.

Purpose: Circulating tumor DNA in plasma may present a minimally invasive opportunity to identify tumor-derived mutations to inform selection of targeted therapies for individual patients, particularly in cases of oligometastatic disease where biopsy of multiple tumors is impractical. To assess the utility of plasma DNA as a "liquid biopsy" for precision oncology, we tested whether sequencing of plasma DNA is a reliable surrogate for sequencing of tumor DNA to identify targetable genetic alterations.

Methods: Blood and biopsies of 1-3 tumors were obtained from 4 evaluable patients with advanced breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05714-2DOI Listing

Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population.

Breast Cancer Res Treat 2020 Aug 19;182(3):739-750. Epub 2020 Jun 19.

Pharmacy Discipline, Life Science School, Khulna University, Khulna, 9208, Bangladesh.

Background: Genetic polymorphisms in DNA repair genes, XRCC1 (Arg399Gln) and XRCC3 (Thr241Met), may affect their DNA repair capacity leading to individual variation in breast cancer susceptibility among Bangladeshi females.

Methods: The case-control study comprised 121 breast cancer patients and 133 healthy controls. Genomic DNA isolated from peripheral blood was genotyped for target SNPs using PCR-RFLP method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05738-8DOI Listing

ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HRHER2 breast cancer patients.

Breast Cancer Res Treat 2020 Aug 19;182(3):601-612. Epub 2020 Jun 19.

Cancer Biology Training Program, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.

Purpose: The ETS transcription factor ESE-1 has been shown to be important in HER2 breast cancer and ESE-1 mRNA expression has been shown to associate with prognostic outcomes in the HER2 subtype, as well as in ER, HER2 luminal B patients. However, the clinical significance of ESE-1 protein expression remains unknown. The purpose of the current exploratory study is to evaluate the prognostic value of ESE-1 protein expression in molecular breast cancer subtypes with special emphasis on hormone receptor positive HER2(HR HER2) and the HER2 positive (HER2-only) breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05734-yDOI Listing

Chronic adverse effects after an axillary lymphadenectomy in breast cancer patients after administering weaker and stronger postoperative analgesia: results of a prospective double-blind randomized study.

Breast Cancer Res Treat 2020 Aug 18;182(3):655-663. Epub 2020 Jun 18.

Department of Anesthesiology, Institute of Oncology, Zaloska 2, 1000, Ljubljana, Slovenia.

Purpose: The aim of this study was to compare the rate of chronic adverse effects after a weaker and stronger postoperative analgesia.

Methods: A prospective double-blind randomized study included 117 breast cancer patients receiving tramadol for pain relief for 4 weeks after an axillary lymphadenectomy from 2015 to 2018. Patients with a larger dose received 75/650 mg of tramadol with paracetamol every 8 h and a group with a lower dose received 37. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05713-3DOI Listing

Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?

Breast Cancer Res Treat 2020 Aug 16;182(3):527-530. Epub 2020 Jun 16.

Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.

Purpose: The Coronavirus pandemic has exposed substantial racial and ethnic health and healthcare disparities. Black breast cancer patients face significant disparities in stage of presentation, surgical management, and mortality. The objective of this editorial is to examine the possible implications of the surgical delay imposed by the pandemic on black breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05740-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298443PMC

Re: Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.

Breast Cancer Res Treat 2020 08 13;182(3):763-764. Epub 2020 Jun 13.

Setor de Mastologia, Hospital das Clínicas,Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05742-yDOI Listing

The bottom line for lesion localization in breast cancer.

Authors:
M Ahmed

Breast Cancer Res Treat 2020 Aug 13;182(3):523-525. Epub 2020 Jun 13.

Division of Surgery and Interventional Science, University College London, Royal Free Hospital, 9th Floor (East), Pond Street, London, NW3 2QG, UK.

The development of radioisotope-independent, wire-free localization techniques for excision of non-palpable breast cancer will continue to expand rapidly within the next few years, increasing market competition. It is imperative that the introduction of these new technologies is correctly evaluated in terms of their major logistical benefits in streamlining pathways from radiology to the operating theatre and subsequent financial savings, rather than focusing upon margin re-excision rates-in which they are unlikely to advance current practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05735-xDOI Listing
August 2020
3.940 Impact Factor